The impact of pseudoephedrine regulation at Australian pharmacies through Project Stop: A narrative review.
methamphetamine
pharmacy
policing
precursor
real-time monitoring
Journal
Drug and alcohol review
ISSN: 1465-3362
Titre abrégé: Drug Alcohol Rev
Pays: Australia
ID NLM: 9015440
Informations de publication
Date de publication:
14 Nov 2023
14 Nov 2023
Historique:
revised:
19
10
2023
received:
29
06
2023
accepted:
23
10
2023
medline:
15
11
2023
pubmed:
15
11
2023
entrez:
14
11
2023
Statut:
aheadofprint
Résumé
Project Stop, a real-time monitoring program for pseudoephedrine-containing medicines, was initiated in 2005 by the Pharmacy Guild of Australia in collaboration with police in the state of Queensland. The program implemented an online database to record pseudoephedrine purchases (and attempted purchases) to prevent large-scale diversion to methamphetamine production. This narrative review aims to understand the overall impact of Project Stop, what evidence exists for this kind of intervention in Australia, and what lessons can be learned from its introduction. Systematic database searches were conducted in Embase, PubMed, Web of Science and Google Scholar, with 20 relevant sources selected for inclusion. Project Stop successfully prevented some pseudoephedrine from being diverted from pharmacies to methamphetamine production. The intervention has been most effective in jurisdictions that made the program mandatory. Project Stop was also associated with a temporary decline in clandestine laboratory seizures in Queensland, changes in methamphetamine production methods and reduced voluntary treatment admissions for methamphetamine use. Implementation was not associated with an appreciable effect on secondary indicators, such as methamphetamine production and harmful use. Future applications of a Project Stop model must ensure ongoing impact evaluation, assessment of its effect on individual's drug-related behaviour and combine it with policies that address drug use as a health issue. Project Stop has been narrowly successful in terms of reducing pseudoephedrine diversion and demonstrates the potential for third-party policing practices directed at the consumer level, in collaboration with healthcare practitioners, rather than only regulating precursor wholesalers.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Australian Research Council
ID : FT220100186
Informations de copyright
© 2023 The Authors. Drug and Alcohol Review published by John Wiley & Sons Australia, Ltd on behalf of Australasian Professional Society on Alcohol and other Drugs.
Références
Farrell M, Martin NK, Stockings E, Borquez A, Cepeda JA, Degenhardt L, et al. Responding to global stimulant use: challenges and opportunities. Lancet. 2019;394:1652-1667.
Stoneberg DM, Shukla RK, Magness MB. Global methamphetamine trends. Int Crim Justice Rev. 2017;28:136-161.
Australian institute of Health and welfare. National Drug Strategy Household Survey 2019. Canberra. 2020.
Vidal S, Décary-Hétu D. Shake and bake: exploring drug producers’ adaptability to legal restrictions through online methamphetamine recipes. J Drug Issues. 2018;48:269-284.
Cherney A, O'Reilly J, Grabosky P. Networks and meta-regulation: strategies aimed at governing illicit synthetic drugs. Policing Soc. 2006;16:370-385.
Mazerolle L, Ransley J. Third party policing. London: Cambridge University Press; 2005.
Cunningham JK, Liu LM. Guidelines for measuring impacts of methamphetamine precursor chemical regulations: a reply to Reuter and Caulkins (2003). Addiction. 2003;98:1463-1464.
Cunningham JK, Liu LM. Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine-related hospital admissions. Addiction. 2003;98:1229-1237.
Cunningham JK, Liu LM. Impact of methamphetamine precursor chemical legislation, a suppression policy, on the demand for drug treatment. Soc Sci Med. 2008;66:1463-1473.
Cunningham JK, Callaghan RC, Tong D, Liu LM, Li HY, Lattyak WJ. Changing over-the-counter ephedrine and pseudoephedrine products to prescription only: impacts on methamphetamine clandestine laboratory seizures. Drug Alcohol Depend. 2012;126:55-64.
Shukla RK, Elaine BE. Responding to clandestine methamphetamine manufacturing: a case study in situational crime prevention. Crim Justice Policy Rev. 2009;21:338-362.
McBride DC, Terry-McElrath YM, Chriqui JF, O'Connor JC, VanderWaal CJ, Mattson KL. State methamphetamine precursor policies and changes in small toxic lab methamphetamine production. J Drug Issues. 2011;41:253-282.
Cunningham JK, Maxwell JC, Campollo O, Liu LM, Lattyak WJ, Callaghan RC. Mexico's precursor chemical controls: emergence of less potent types of methamphetamine in the United States. Drug Alcohol Depend. 2013;129:125-136.
Chiu YN, Leclerc B, Townsley M. Crime script analysis of drug manufacturing in clandestine laboratories: implications for prevention. Br J Criminol. 2011;51:355-374.
Dobkin C, Nicosia N, Weinberg M. Are supply-side drug control efforts effective? Evaluating OTC regulations targeting methamphetamine precursors. J Public Econ. 2014;120:48-61.
Petruzelka B, Bartak M. The identification of precursor regulation impact on the methamphetamine market and public health indicators in The Czech Republic: time series structural break analysis. Int J Environ Res Public Health. 2020;17:7840.
Copes H, Hochstetler A. The social organization of methamphetamine manufacturing: roles, identities and persistence. J Crim Justice. 2021;73:101795.
Deitzer JR, Leban L, Copes H. “The times have changed, the dope has changed”: Women's cooking roles and gender performances in shake methamphetamine markets. Crim. 2019;57:268-288.
Melnikova N, Orr MF, Wu J, Christensen B. Injuries from methamphetamine-related chemical incidents-Five states, 2001-2012. MMWR Morb Mortal Wkly Rep. 2015;64:909-912.
McKetin R, Sutherland R, Bright DA, Norberg MM. A systematic review of methamphetamine precursor regulations. Addiction. 2011;106:1911-1924.
McKetin R. Methamphetamine precursor regulation: are we controlling or diverting the drug problem? Addiction. 2008;103:521-523.
Ransley J, Mazerolle L, Manning M, Mcguffog I, Drew JM, Webster JL. Reducing the methamphetamine problem in Australia: evaluating innovative partnerships between police, pharmacies and other third parties. NDLERF. 2011.
Parliamentary Joint Committee of the Australian Crime Commission. Inquiry into the manufacture, importation and use of amphetamines and other synthetic drugs (AOSD) in Australia. 2007.
Tan ACW, Emmerton L. Non-prescription medicines: current issues in Australian community pharmacy. Int J Pharm Pract. 2009;17:207-213.
Manning M, Ransley J, Smith C, Mazerolle L, Cook A. Policing methamphetamine problems: a framework for synthesising expert opinion and evaluating alternative policy options. J Public Policy. 2013;33:371-396.
Webster J. Assessing community pharmacist engagement in a policing partnership strategy to reduce the illicit diversion of pseudoephedrine products. Res Social Adm Pharm. 2013;9:903-917.
Devaney M, Ferris J, Mazerolle L. Online reporting of pseudoephedrine pharmacy sales: does Australia require a mandatory system? Int J Pharm Pract. 2015;23:248-255.
Webster J. Effective third-party policing partnerships or missed opportunities? Polic Soc. 2015;25:97-114.
Hattingh HL, Varsani J, Kachouei LA, Parsons R. Evaluation of pseudoephedrine pharmacy sales before and after mandatory recording requirements in Western Australia: a case study. Subst Abuse Treat Prev Policy. 2016;11:30.
Manning M, Wong GTW, Ransley J, Smith C. Analysing pseudoephedrine/methamphetamine policy options in Australia using multi-criteria decision modelling. Int J Drug Policy. 2016;32:85-92.
Mazerolle L, McGuffog I, Ferris J, Chamlin MB. Pharmaceutical sales of pseudoephedrine: the impact of electronic tracking systems on methamphetamine crime incidents. Addiction. 2017;112:468-474.
Webster J, Mazerolle P, Ransley J, Mazerolle L. Disrupting domestic ‘ice’ production: deterring drug runners with a third-party policing intervention. Policing Soc. 2018;28:1025-1037.
Drew JM. Police responses to the methamphetamine problem: an analysis of the organizational and regulatory context. Police Q. 2011;14:99-123.
Berbatis CG, Sunderland VB, Dhaliwal SS. Linked electronic medication systems in community pharmacies for preventing pseudoephedrine diversion: a review of international practice and analysis of results in Australia. Drug Alcohol Rev. 2009;28:586-591.
Crime and Misconduct Commission. Illicit drug markets in Queensland: A strategic assessment. 2010.
Ritter A, Bright D, Gong W. Evaluating drug law enforcement interventions directed towards methamphetamine in Australia. 2012.
Ferris J, Devaney M, Mazerolle L, Sparkes-Carroll M. Assessing the utility of Project STOP in reducing pseudoephedrine diversion to clandestine laboratories. Australian Institute of Criminology. 2016.
Pharmacy Guild of Australia. Submission to the Parliamentary Joint Committee on the Australian Crime Commission Inquiry into Amphetamines and Other Synthetic Drugs (AOSD). 2006.
Gluckman P. Consideration of reduction of access to, or elimination of, pseudoephedrine in ‘cold and flu’ preparations: Report to the Prime Minister. 2009.
Australian Crime Commission. Submission to Select Committee of the Legislative Assembly of the Northern Territory Inquiry into methylamphetamine. 2015.
McGuffog I. Drug use and drug control policy: evaluating the impact of precursor regulation on drug user behaviour: Griffith University. 2012.
Gupte J. Pseudo alert for pharmacy. Aust J Pharm. 2010;91:3.
Man N, Sisson SA, McKetin R, Chrzanowska A, Bruno R, Dietze PM, et al. Trends in methamphetamine use, markets and harms in Australia, 2003-2019. Drug Alcohol Rev. 2022;41:1041-1052.
Queensland Health. Queensland Health methamphetamine paper. 2017.
Coyne J, White V, Alvarez C. Methamphetamine: focusing Australia's National ice Strategy on the problem, not the symptoms. Australian Strategic Policy Institute. 2015.
Commonwealth of Australia. National Ice Action Strategy 2015. 2015.
Department of Health. National Ice Action Strategy Rollout. 2019.
Department of Health. National Drug Strategy 2017-2026. 2017.
Puljevic C, Zahnow R, Benfer I, Winstock AR, Maier LJ, Barratt MJ, et al. Patterns of methamphetamine production among an international sample of methamphetamine ‘cooks’. Drug Alcohol Rev. 2021;40:1287-1293.
Erickson JH, Hochstetler A, Copes H. Meth cooking as a job: identity and dirty work. Justice Q. 2019;38:1-21.
Sexton R, Carlson RG, Leukefeld CG, Booth BM. Methamphetamine producers and users’ reactions to pseudoephedrine legislation in the rural south. J Crim Justice. 2008;31:117-137.
Brookfield SJ, Selvey L, Maher L, Fitzgerald L. “It Just Kind of Cascades”: a critical ethnography of methamphetamine-related pleasure among people in recovery. Int J Drug Policy. 2021;98:103427.
Garami J, Valikhani A, Parkes D, Haber P, Mahlberg J, Misiak B, et al. Examining perceived stress, childhood trauma and interpersonal trauma in individuals with drug addiction. Psychol Rep. 2019;122:433-450.
Mulia N, Schmidt L, Bond J, Jacobs L, Korcha R. Stress, social support and problem drinking among women in poverty. Addiction. 2008;103:1283-1293.
Pereira M, Scott J, Beem A. Imaginary drug control and the failures of contemporary Australian drug policy. Contemp Drug Probl. 2020;47:29-42.
Parliamentary Joint Committee on Law Enforcement. Inquiry into crystal methamphetamine (ice). Final report. 2018.
Parliamentary Joint Committee on Law Enforcement. Hansard Transcript: Wednesday, 12 August 2015. 2015.